Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as foretinib (formerly GSK1363089 or XL880), GSK1363089 (formerly XL880)
Foretinib · 4 trials · 4 indications
All patients will be assessed for response at the end of every second cycle (every 8 weeks). Response and progression will be evaluated using RECIST 1.1.
Overall response rate is the percentage of participants for whom the best overall response to the study drug was a confirmed partial response (PR) or confirmed complete response (CR). Best overall response and its associated confirmation criteria, RECIST; Version 1.0) was based on the Investigator's assessment of the target and non target lesions.
Adverse events will be graded using CTCAE V4.0
| Arm | Type | Description |
|---|---|---|
| Foretinib | EXPERIMENTAL | - |
| 5/9 dosing | EXPERIMENTAL | 240 mg of foretinib on a 5 day on / 9 day off regimen every 14 days. |
| daily dosing | EXPERIMENTAL | 80 mg foretinib on a daily dosing regimen |
| Foretinib and Lapatinib | EXPERIMENTAL | Patients will receive foretinib as a continuous oral dose, and lapatinib as a continuous oral dose. Lapatinib will commence on Day1, Cycle 1 and foretinib will commence on Day 3, Cycle 1. |
| Name | Type | Description |
|---|---|---|
| Foretinib | DRUG | foretinib, at a continuous oral daily dose of 60 mg |
| foretinib (formerly GSK1363089 or XL880) | DRUG | treatment with oral foretinib on one of 2 dosing regimens: 240 mg on a 5 day on / 9 day off schedule every 14 days, or 80 mg on a daily dosing schedule |
| Lapatinib | DRUG | Daily oral dosing at assigned dose beginning day 1 cycle 1. |
Inclusion Criteria: * Histologically or cytologically confirmed diagnosis of invasive breast cancer, that is estrogen receptor (ER) negative, progesterone receptor (PR) negative and human epidermal growth factor receptor 2 (HER2) negative. * Formalin fixed paraffin embedded tissue available for cen...
Foretinib is an investigational small molecule kinase inhibitor being developed by GSK plc for the treatment of solid tumors. It has been studied in breast cancer, hepatocellular carcinoma, and renal cell carcinoma. It is not approved and remains in clinical development, with completed trials in recurrent breast cancer, metastatic breast cancer, liver cancer, and papillary renal cell carcinoma.
Foretinib has been studied in recurrent and metastatic breast cancer, hepatocellular carcinoma, and renal cell carcinoma, including papillary renal cell carcinoma. All of these are investigational uses in clinical trials, not approved indications. The trials were conducted in Canada, the United States, Hong Kong, Taiwan, and Thailand.
Foretinib inhibits the kinases KIT, TEK, FLT1, FLT4, KDR, and MET. It is a small molecule inhibitor targeting these receptor tyrosine kinases, which are involved in tumor growth, angiogenesis, and cell signaling pathways relevant to cancer progression.
Foretinib is being developed by GSK plc, which trades under the ticker GSK. GSK sponsored the clinical trials studying foretinib in breast cancer, hepatocellular carcinoma, and renal cell carcinoma.
Foretinib is in Phase 1 development and is investigational. It has not been approved by the FDA. Clinical trials have been completed, including Phase 1 and Phase 2 studies, but no active trials are currently ongoing.
Foretinib has been studied in four completed clinical trials: NCT01147484 in recurrent or metastatic breast cancer, NCT01138384 in combination with lapatinib in metastatic breast cancer, NCT00920192 in hepatocellular carcinoma, and NCT00726323 in papillary renal cell carcinoma. All trials are completed and no active trials are ongoing.
Yes, foretinib is the same drug as GSK1363089 and XL880. Foretinib was formerly known by these names, and the trial NCT00726323 was conducted under the name GSK1363089, formerly XL880, for papillary renal cell carcinoma.